Amryt says integration of acquired company Aegerion ‘progressing well’
Dublin-based biopharma company has cash position of $60.9m
Amryt Pharma focuses on developing treatments to help patients with rare and orphan diseases. Photograph: iStock
The company, which focuses on developing treatments to help patients with rare and orphan diseases, noted that its cash position of $60.9 million (€54.7m), helped by its $57 million fundraising in September, was significantly ahead of expectations at this point.
“Amryt has evolved from a company with a single asset on the market in the Europe, the Middle East and Africa [EMEA] to become a global biopharmaceutical company with two orphan disease products and a commercial infrastructure across North America, EMEA and Latin America.
“Our strategy is to become a global leader in rare and orphan diseases, and we are committed to delivering new therapies to patients in areas of high unmet need,” said Amryt chief executive Joe Wiley.
He added that the company was pleased with the progress being made on the integration of Aegerion, adding that synergies achieved so far have resulted in a higher cash balance at this point than was initially forecast.